治疗期间VEGF表达降低可能是转移性结直肠癌患者对一线FOLFIRI联合贝伐单抗治疗反应性的一个预测指标。
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
作者信息
Tsai Hsiang-Lin, Lin Chih-Hung, Huang Ching-Wen, Yang I-Ping, Yeh Yung-Sung, Hsu Wen-Hung, Wu Jeng-Yih, Kuo Chao-Hung, Tseng Fan-Ying, Wang Jaw-Yuan
机构信息
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University Kaohsiung, Taiwan ; Division of General Surgery Medicine, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung, Taiwan ; Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung, Taiwan ; Program of Bachelor of Health Beauty, School of Medical and Health Sciences, Fooyin University Kaohsiung, Taiwan ; Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University Kaohsiung, Taiwan ; Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University Kaohsiung, Taiwan.
Deaprtment of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung, Taiwan.
出版信息
Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015.
OBJECTIVE
Bevacizumab is the only anti-angiogenic agent approved in first-line therapy for metastatic colorectal cancer (mCRC). Although chemotherapy plus bevacizumab has led to improve outcomes for mCRC patients and is a common choice for first-line treatment of mCRC, previous research has established no prominent biomarker that can help to select patients who may benefit from bevacizumab in order to improve cost-effectiveness and therapeutic outcomes. The aim of this study was to compare pre- and post-therapeutic VEGF immunohistochemical (IHC) expression in mCRC patients treated with FOLFIRI plus bevacizumab to identify its potential role as a predictive biomarker.
METHODS
A total of 57 mCRC patients who underwent FOLFIRI combined with bevacizumab chemotherapy as a first-line neoadjuvant regimen were enrolled and clinical outcome data analyzed.
RESULTS
Low post-therapeutic VEGF expression (P < 0.001) and decreased peri-therapeutic VEGF expression (P < 0.001) were significantly predictive factors of responders. Furthermore, the 6-month progression-free survival (PFS) rate in mCRC patients with decreased peri-therapeutic VEGF expression was significantly better than the rate for those patients with no peri-therapeutic VEGF expression alterations (P = 0.033).
CONCLUSIONS
Decreased peri-therapeutic VEGF expression in mCRC patients could probably be used to predict responsiveness to bevacizumab and subsequent PFS in clinical practice.
目的
贝伐单抗是唯一被批准用于转移性结直肠癌（mCRC）一线治疗的抗血管生成药物。尽管化疗联合贝伐单抗已改善了mCRC患者的预后，且是mCRC一线治疗的常用选择，但既往研究尚未确立可帮助选择可能从贝伐单抗治疗中获益的患者的显著生物标志物，以提高成本效益和治疗效果。本研究旨在比较接受FOLFIRI联合贝伐单抗治疗的mCRC患者治疗前后的VEGF免疫组化（IHC）表达，以确定其作为预测生物标志物的潜在作用。
方法
共纳入57例接受FOLFIRI联合贝伐单抗化疗作为一线新辅助方案的mCRC患者，并分析临床结局数据。
结果
治疗后VEGF低表达（P<0.001）和治疗期间VEGF表达降低（P<0.001）是反应者的显著预测因素。此外，治疗期间VEGF表达降低的mCRC患者的6个月无进展生存期（PFS）率显著优于治疗期间VEGF表达无改变的患者（P=0.033）。
结论
mCRC患者治疗期间VEGF表达降低可能可用于在临床实践中预测对贝伐单抗的反应及随后的PFS。
Zotero 插件